• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

介入性 MRI 引导下的纹状体 AAV2-GDNF 递呈用于帕金森病的计划性临床试验。

Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.

机构信息

Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143-0112, USA.

出版信息

Mol Ther. 2011 Jun;19(6):1048-57. doi: 10.1038/mt.2011.11. Epub 2011 Feb 22.

DOI:10.1038/mt.2011.11
PMID:21343917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3129792/
Abstract

Clinical trials involving direct infusion of neurotrophic therapies for Parkinson's disease (PD) have suffered from poor coverage of the putamen. The planned use of a novel interventional-magnetic resonance imaging (iMRI) targeting system for achieving precise, real-time convection-enhanced delivery in a planned clinical trial of adeno-associated virus serotype 2 (AAV2)-glial-derived neurotrophic factor (GDNF) in PD patients was modeled in nonhuman primates (NHP). NHP received bilateral coinfusions of gadoteridol (Gd)/AAV2-GDNF into two sites in each putamen, and three NHP received larger infusion volumes in the thalamus. The average targeting error for cannula tip placement in the putamen was <1 mm, and adjacent putamenal infusions were distributed in a uniform manner. GDNF expression patterns in the putamen were highly correlated with areas of Gd distribution seen on MRI. The distribution volume to infusion volume ratio in the putamen was similar to that in the thalamus, where larger infusions were achieved. Modeling the placement of adjacent 150 and 300 µl thalamic infusions into the three-dimensional space of the human putamen demonstrated coverage of the postcommissural putamen, containment within the striatum and expected anterograde transport to globus pallidus and substantia nigra pars reticulata. The results elucidate the necessary parameters for achieving widespread GDNF expression in the putamenal motor area and afferent substantia nigra of PD patients.

摘要

临床研究表明,直接输注神经营养因子治疗帕金森病(PD)的效果不佳,无法完全覆盖壳核。为了在计划开展的帕金森病患者腺相关病毒血清型 2(AAV2)-胶质细胞源性神经营养因子(GDNF)临床试验中实现精确、实时的对流增强递送,计划使用一种新型的介入磁共振成像(iMRI)靶向系统。该系统在非人类灵长类动物(NHP)中进行了建模。NHP 双侧壳核内各两个部位共输注了钆特醇(Gd)/AAV2-GDNF,3 只 NHP 在丘脑内接受了更大的输注体积。在壳核内放置导管尖端的平均靶向误差<1 毫米,且相邻壳核内的输注呈均匀分布。壳核内 GDNF 的表达模式与 MRI 上 Gd 分布的区域高度相关。壳核内的分布体积与输注体积比与丘脑相似,在丘脑内实现了更大的输注体积。将相邻的 150 和 300µl 丘脑输注物放置在人类壳核的三维空间中,模拟了对壳核后连合区的覆盖,包含在纹状体内部,并预期向苍白球和黑质网状部进行顺行转运。这些结果阐明了在 PD 患者壳核运动区和黑质传入区实现广泛 GDNF 表达所需的参数。

相似文献

1
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.介入性 MRI 引导下的纹状体 AAV2-GDNF 递呈用于帕金森病的计划性临床试验。
Mol Ther. 2011 Jun;19(6):1048-57. doi: 10.1038/mt.2011.11. Epub 2011 Feb 22.
2
Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.MRI 引导下向帕金森病患者壳核中注射 AAV2-GDNF 和钆喷酸葡胺的长期安全性。
Mol Ther. 2022 Dec 7;30(12):3632-3638. doi: 10.1016/j.ymthe.2022.08.003. Epub 2022 Aug 10.
3
Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.在老年恒河猴的多巴胺能黑质纹状体通路中,增强型输送 AAV2-GDNF 的临床相关作用。
Hum Gene Ther. 2009 May;20(5):497-510. doi: 10.1089/hum.2008.137.
4
Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.帕金森病患者纹状体注射 AAV2-GDNF45 个月后持续表达 GDNF。
Mov Disord. 2024 Aug;39(8):1412-1417. doi: 10.1002/mds.29820. Epub 2024 May 8.
5
Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.胶质细胞源性神经营养因子基因转移治疗帕金森病:AAV2 载体在灵长类动物大脑中的顺行分布。
Neurobiol Dis. 2012 Nov;48(2):228-35. doi: 10.1016/j.nbd.2011.10.004. Epub 2011 Oct 14.
6
Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.AAV2-GDNF 在大鼠基底节中的顺行轴突转运。
Mol Ther. 2011 May;19(5):922-7. doi: 10.1038/mt.2010.248. Epub 2010 Nov 23.
7
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.AAV2-GDNF 基因转移到老龄和帕金森病恒河猴多巴胺能黑质纹状体通路的安全性评估。
Hum Gene Ther. 2009 Dec;20(12):1627-40. doi: 10.1089/hum.2009.103.
8
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen.图像引导下的 GDNF 蛋白向猴壳核的对流增强递送。
Neuroimage. 2011 Jan;54 Suppl 1:S189-95. doi: 10.1016/j.neuroimage.2010.01.023. Epub 2010 Jan 18.
9
Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.将2型腺相关病毒(AAV2)对流增强递送至纹状体以及AAV2在猴脑内的运输。
Hum Gene Ther. 2006 Mar;17(3):291-302. doi: 10.1089/hum.2006.17.291.
10
Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.实时磁共振成像与钆喷酸葡胺预测腺相关病毒 2 载体通过增强传递后转基因的分布。
Mol Ther. 2010 Aug;18(8):1490-5. doi: 10.1038/mt.2010.114. Epub 2010 Jun 15.

引用本文的文献

1
Striatal GluN2A gene suppression reduces L-DOPA-induced abnormal involuntary movements in parkinsonian rats.纹状体GluN2A基因抑制可减少帕金森病大鼠中左旋多巴诱导的异常不自主运动。
Neuropharmacology. 2025 Jul 29;279:110616. doi: 10.1016/j.neuropharm.2025.110616.
2
Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications.神经退行性疾病中的病毒载体:免疫反应与治疗应用
Front Neurol. 2025 Jun 18;16:1603125. doi: 10.3389/fneur.2025.1603125. eCollection 2025.
3
Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease.腺相关病毒2型-胶质细胞源性神经营养因子经脑室内注射治疗轻度或中度帕金森病
Mov Disord. 2025 May 20. doi: 10.1002/mds.30193.
4
Neuroimaging techniques, gene therapy, and gut microbiota: frontier advances and integrated applications in Alzheimer's Disease research.神经成像技术、基因治疗与肠道微生物群:阿尔茨海默病研究中的前沿进展与综合应用
Front Aging Neurosci. 2024 Dec 3;16:1485657. doi: 10.3389/fnagi.2024.1485657. eCollection 2024.
5
Neurosurgical gene therapy for central nervous system diseases.神经外科基因治疗中枢神经系统疾病。
Neurotherapeutics. 2024 Jul;21(4):e00434. doi: 10.1016/j.neurot.2024.e00434. Epub 2024 Aug 26.
6
The Influence of Size on the Intracranial Distribution of Biomedical Nanoparticles Administered by Convection-enhanced Delivery in Minipigs.尺寸对通过对流增强递送在小型猪中给药的生物医学纳米颗粒颅内分布的影响。
ACS Nano. 2024 Jul 9;18(27):17869-17881. doi: 10.1021/acsnano.4c04159. Epub 2024 Jun 26.
7
Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.帕金森病患者纹状体注射 AAV2-GDNF45 个月后持续表达 GDNF。
Mov Disord. 2024 Aug;39(8):1412-1417. doi: 10.1002/mds.29820. Epub 2024 May 8.
8
GDNF gene therapy for alcohol use disorder in male non-human primates.GDNF 基因治疗男性非人类灵长类动物的酒精使用障碍。
Nat Med. 2023 Aug;29(8):2030-2040. doi: 10.1038/s41591-023-02463-9. Epub 2023 Aug 14.
9
An update on advanced therapies for Parkinson's disease: From gene therapy to neuromodulation.帕金森病先进疗法的最新进展:从基因治疗到神经调节。
Front Surg. 2022 Sep 23;9:863921. doi: 10.3389/fsurg.2022.863921. eCollection 2022.
10
Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.MRI 引导下向帕金森病患者壳核中注射 AAV2-GDNF 和钆喷酸葡胺的长期安全性。
Mol Ther. 2022 Dec 7;30(12):3632-3638. doi: 10.1016/j.ymthe.2022.08.003. Epub 2022 Aug 10.

本文引用的文献

1
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.用于MRI引导下对流增强治疗药物递送的新型平台:在非人灵长类动物大脑中的临床前验证
Stereotact Funct Neurosurg. 2011;89(3):141-51. doi: 10.1159/000323544. Epub 2011 Apr 14.
2
Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease.I 期研究中用于治疗帕金森病的腺相关病毒血清型 2-人芳香族 L-氨基酸脱羧酶基因治疗的定性成像。
Neurosurgery. 2010 Nov;67(5):1377-85. doi: 10.1227/NEU.0b013e3181f53a5c.
3
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.AAV2-GDNF 经对流增强递送后对 MPTP 损伤的多巴胺能系统的再生。
J Neurosci. 2010 Jul 14;30(28):9567-77. doi: 10.1523/JNEUROSCI.0942-10.2010.
4
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease.芳香族 L-氨基酸脱羧酶基因治疗帕金森病的 I 期研究。
Mol Ther. 2010 Sep;18(9):1731-5. doi: 10.1038/mt.2010.135. Epub 2010 Jul 6.
5
Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.实时磁共振成像与钆喷酸葡胺预测腺相关病毒 2 载体通过增强传递后转基因的分布。
Mol Ther. 2010 Aug;18(8):1490-5. doi: 10.1038/mt.2010.114. Epub 2010 Jun 15.
6
Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders.磁共振成像引导腺相关病毒 2 递送至灵长类动物大脑治疗溶酶体贮积症。
Hum Gene Ther. 2010 Sep;21(9):1093-103. doi: 10.1089/hum.2010.040.
7
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen.图像引导下的 GDNF 蛋白向猴壳核的对流增强递送。
Neuroimage. 2011 Jan;54 Suppl 1:S189-95. doi: 10.1016/j.neuroimage.2010.01.023. Epub 2010 Jan 18.
8
Poor drug distribution as a possible explanation for the results of the PRECISE trial.可能是药物分发不良导致 PRECISE 试验的结果。
J Neurosurg. 2010 Aug;113(2):301-9. doi: 10.3171/2009.11.JNS091052.
9
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.壳核芳香族氨基酸脱羧酶基因治疗帕金森病的安全性和耐受性
Neurology. 2009 Nov 17;73(20):1662-9. doi: 10.1212/WNL.0b013e3181c29356. Epub 2009 Oct 14.
10
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.在人和非人灵长类动物中,进行图像引导的对流增强递药治疗时,壳核的最佳区域。
Neuroimage. 2011 Jan;54 Suppl 1:S196-203. doi: 10.1016/j.neuroimage.2009.08.069. Epub 2009 Sep 15.